2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid

Intermediate for Venetoclax. Venetoclax (trade name Venclexta) is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality. Venetoclax is a BH3-mimetic and acts as a Bcl-2 inhibitor. Venetoclax has been approved by US FDA om April 11, 2016.

Specifications

Product Name:                  2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid

Synonyms:                         N/A

CAS Number:                     1235865-77-6

Molecular Weight:            571.1175

Molecular Formula:          C33H35ClN4O3

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               Clc1ccc(cc1)C1=C(CCC(C1)(C)C)CN1CCN(CC1)c1ccc(c(c1)Oc1cnc2c(c1)cc[nH]2)C(=O)O

2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid

  • $600.00
  • Ex Tax: $600.00

Available Options